Abstract 537P
Background
Stereotactic ablative radiotherapy (SABR) has been shown to sensitize immunotherapy through inducing immunogenic death and remodeling the tumor immune microenvironment. Anti-angiogenic therapy exhibits synergistic antitumor effects with PD-1 antibodies through its immunomodulatory effects for metastatic colorectal cancer (mCRC) patients. Here, we report the updated findings from RIFLE trial: the efficacy and safety of the combination of fruquintinib, PD-1 inhibitor tislelizumab and SABR in mCRC patients.
Methods
RIFLE is a single-center, single-arm, prospective phase II clinical trial (NCT04948034). mCRC patients with at least 2 measurable lesions who have failed ≥ 1L standard therapy will receive SABR followed by fruquintinib (5 mg, d1-14, qd) and tislelizumab (200 mg, d1, q3w) within two weeks from completion of radiation. The primary endpoint is the objective response rate (ORR). The secondary endpoints include disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate and toxicity.
Results
From August 2021 to April 2024, 38 patients were included and 35 in the efficacy analysis. Median age was 59 years, 27 (77.1%) patients were male, 30(85.7%) had ≥ 3 metastases, and 16 (45.7%) had received ≥ 3 prior lines of systemic therapy. The biological effective dose (BED) for irradiated lesions ranged from 37.5 to 105 Gy. Median study follow-up was 17.8 months (95%CI:12.101-23.499), 1 patient achieved complete response (CR) for target lesions, 11 partial response (PR), 15 stable disease (SD), illustrating an ORR of 34.3% and a DCR of 77.1%. Median PFS was 8.8 months (95%CI:6.200-11.400). The most common treatment-related adverse events (TRAEs) were proteinuria (34.3%), hypertension (22.9%) and rash (17.1%). Grade 3-4 AEs occurred in 9 patients, including proteinuria and hypertension, and there were no treatment-related deaths.
Conclusions
SABR combined with tislelizumab and fruquintinib shows promising effects and good safety in the treatment of metastatic colorectal cancer, which is expected to provide new therapeutic strategies and improve the prognosis for mCRC patients.
Clinical trial identification
NCT04948034, FDRT-2020-274-2194. Initial Release: 06/23/2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hutchison MediPharma Co., Ltd and BeiGene (Beijing) Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Presenter: Priya Thomas
Session: Poster session 15
425P - The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries
Presenter: Alicia Annamalay
Session: Poster session 15
426P - Impact of statin therapy on mortality and recurrence in female breast cancer: A meta-analysis
Presenter: Maria Eduarda Souza
Session: Poster session 15
427P - The role of patient navigation (PN) in delivering goal-concordant care to advanced breast cancer (ABC) patients
Presenter: Akshara Singareeka Raghavendra
Session: Poster session 15
428P - Key landmarks of male advanced breast cancer: Results of the GEICAM/2016-04 study
Presenter: Noelia Martinez
Session: Poster session 15
429P - Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives
Presenter: Ana Leonor Matos
Session: Poster session 15
430P - A novel survival predicting model for breast cancer brain metastasis based on multimodal data
Presenter: Zisheng Wu
Session: Poster session 15
431P - Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)
Presenter: Hope Rugo
Session: Poster session 15
432P - Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04
Presenter: Naoto Ueno
Session: Poster session 15
433TiP - Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC)
Presenter: Sara Tolaney
Session: Poster session 15